(PAVMZ) – PRNewswire
-
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
-
PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results
-
Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results
-
Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
-
Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference
-
PAVmed to Hold a Business Update Conference Call and Webcast on March 27, 2024
-
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024
-
Lucid Diagnostics Provides Update Regarding World Trade Center Health Program
-
Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony
-
Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors
-
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies
-
PAVmed Provides Additional Details for Upcoming Stock Dividend to Shareholders
-
PAVmed Announces Dividend of Lucid Diagnostics Common Stock and Reverse Stock Split
-
Lucid Diagnostics Strengthens and Expands Market Access and Direct Contracting Efforts
-
PAVmed Provides Business Update and Third Quarter Financial Results
-
Lucid Diagnostics Provides Business Update and Third Quarter Financial Results
-
Lucid Diagnostics Launches Next-Generation EsoGuard® Esophageal DNA Test and Announces Upcoming Investor Day
-
Lucid Diagnostics to Present at Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum
-
PAVmed to Hold a Business Update Conference Call and Webcast on November 15, 2023
-
Lucid Diagnostics Announces PREVENT and PREVENT-FF Registries of EsoGuard® Esophageal Precancer Detection
-
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2023
-
PAVmed and Lucid Diagnostics to Participate in Panel Presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference
-
Lucid Diagnostics Releases Positive Data from First Prospective Clinical Utility Study of EsoGuard® Esophageal Precancer Detection
-
Lucid Diagnostics Releases Positive Data Demonstrating Clinical Utility of EsoGuard® Esophageal Precancer Detection in Fire Fighters
-
Lucid Diagnostics Executes First Direct Employer Contract to Provide EsoGuard® Esophageal Precancer Testing as an Employee Benefit
-
PAVmed Provides Business Update and Second Quarter Financial Results
-
Lucid Diagnostics Provides Business Update and Second Quarter Financial Results
-
PAVmed to Hold a Business Update Conference Call and Webcast on August 16, 2023
-
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 15, 2023
-
Lucid Diagnostics to Present at the Canaccord Genuity 43rd Annual Growth Conference
-
PAVmed and Lucid Chairman and Chief Executive Officer, Dr. Lishan Aklog, Testifies at U.S. House of Representatives Energy and Commerce Committee, Hearing on Life-Saving Innovations and Medicare Cover
-
PAVmed Receives 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
-
PAVmed to Participate in Healthcare Virtual Conference Presented by Maxim Group LLC
-
Lucid Diagnostics Launches First EsoGuard® Mobile Test Unit
-
PAVmed Digital Health Subsidiary, Veris Health, Joins Cancer Moonshot's CancerX Partnership as Founding Member
-
PAVmed Provides Business Update and First Quarter Financial Results
-
Lucid Diagnostics Provides Business Update and First Quarter Financial Results
-
Lucid Diagnostics and Collaborators Present New EsoGuard® and EsoCheck® Data at Digestive Disease Week® (DDW) 2023 Conference
-
PAVmed to Hold a Business Update Conference Call and Webcast on May 17, 2023
-
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 16, 2023
-
PAVmed Digital Health Subsidiary, Veris Health, Appoints Gary Manning as President
-
PAVmed Digital Health Subsidiary, Veris Health, to Present Comprehensive Meta-analysis on Impact of Remote Patient Monitoring in Oncology at HIMSS
-
Lucid Diagnostics Reports Publication of Future Effective Foundational Local Coverage Determination by Medicare Administrative Contractor Noridian Healthcare Solutions
-
Lucid Diagnostics to Present at 22nd Annual Needham Virtual Healthcare Conference
-
Lucid Diagnostics Provides Update on Newly Published Future Effective Medicare Local Coverage Determination on Molecular Testing for Detection of Esophageal Precancer and Cancer
-
PAVmed Provides Business Update and Preliminary Fourth Quarter and Full Year 2022 Financial Results
-
/C O R R E C T I O N -- Lucid Diagnostics/
-
Lucid Diagnostics Provides Business Update and Fourth Quarter and Full Year 2022 Financial Results
-
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 14, 2023
-
PAVmed to Hold a Business Update Conference Call and Webcast on March 15, 2023
Back to PAVMZ Stock Lookup
